Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
160 Health InternationalFRA:O66 -5.84%8 Return-on-Tangible-Equity is -151.57% as of Dec. 2025. GuruFocus rates FRA:O66 with a GF Score™ of 8/100. The stock has 5 warning signs investors should review. Among 113 Medical Distribution companies, 160 Health International ranks worse than 98.23% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. 160 Health International's annualized net income for the quarter that ended in Dec. 2025 was €-13.06 Mil. 160 Health International's average shareholder tangible equity for the quarter that ended in Dec. 2025 was €8.62 Mil. Therefore, 160 Health International's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was -151.57%.
The historical rank and industry rank for 160 Health International's Return-on-Tangible-Equity or its related term are showing as below:
FRA:O66'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -371.84 Med: -95.02 Max: -95.02
Current: -371.84
During the past 4 years, 160 Health International's highest Return-on-Tangible-Equity was -95.02%. The lowest was -371.84%. And the median was -95.02%.
FRA:O66's Return-on-Tangible-Equity is ranked worse than 98.23% of 113
companies
in the Medical Distribution industry
Industry Median: 8.78
vs FRA:O66: -371.84
160 Health International (FRA:O66) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
160 Health International Return-on-Tangible-Equity Related Terms
160 Health International Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for 160 Health International's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
160 Health International Return-on-Tangible-Equity Chart
FRA:O66 vs MCK, COR, CAH: Return-on-Tangible-Equity Comparison
For the Medical Distribution subindustry, 160 Health International's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
160 Health International Return-on-Tangible-Equity vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, 160 Health International's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where 160 Health International's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -151.57% mean?
160 Health International (FRA:O66) has a Return-on-Tangible-Equity of -151.57% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on 160 Health International and its competitors. According to the industry distribution chart, 160 Health International ranks #111 out of 113 companies in the Medical Distribution industry, placing it in the top 98.2%.
Is 160 Health International's Return-on-Tangible-Equity too high?
160 Health International's current Return-on-Tangible-Equity is -151.57%. Based on the distribution chart, 160 Health International ranks #111 out of 113 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, 160 Health International has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does 160 Health International's Return-on-Tangible-Equity compare to MCK and COR?
According to the Medical Distribution industry distribution chart, 160 Health International ranks #111 out of 113 companies for Return-on-Tangible-Equity. This places 160 Health International in the lower half of its industry. The industry median Return-on-Tangible-Equity is 8.78. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Distribution company?
The median Return-on-Tangible-Equity among Medical Distribution companies is 8.78, based on 113 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on 160 Health International and its competitors. For the Medical Distribution industry, the median Return-on-Tangible-Equity is 8.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 160 Health International's current Return-on-Tangible-Equity is -151.57%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 160 Health International stock overvalued right now?
160 Health International (FRA:O66) has a current Return-on-Tangible-Equity of -151.57%. The current Return-on-Tangible-Equity is -151.57%. 160 Health International's overall GF Score™ is 8/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For 160 Health International (FRA:O66), the current Return-on-Tangible-Equity is -151.57% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
160 Health International Ltd is an experienced pharmaceutical and healthcare product wholesaler and a digital healthcare integrated service provider in China. The company offers a wide assortment of high-quality pharmaceutical and healthcare products under both wholesale and retail models, to address a spectrum of customer needs. In addition, through its online healthcare and wellness service platform, Healthcare 160 Platform. It also provide digital healthcare and wellness solutions, empowering each Platform Participants, including business customers, medical and healthcare institutions, medical professionals, individual users, and third-party merchants, throughout the healthcare value chain and driving the digital transformation of China's healthcare and wellness industry.
8GF Score
Get the complete analysis for FRA:O66
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:O66 has been successfully added to your 
